Answers are grounded in this paper and cite their sources.
Randomized trial compares acute toxicity and quality-of-life outcomes in high-risk prostate cancer, suggesting benefits for SBRT.
PURPOSE: Stereotactic body radiotherapy (SBRT) to the prostate and pelvis in high-risk prostate cancer (HR-PC) may shorten treatment, but acute toxicity and quality-of-life (QoL) outcomes compared with conventional fractionated intensity-modulated radiotherapy (IMRT) remain uncertain. We report acute toxicity and early QoL outcomes from a randomized phase II trial. METHODS: Between 2019 and 2024, 121 patients with node-negative HR-PC were randomized to SBRT (40 Gy in five weekly fractions to prostate, 36.25 Gy to seminal vesicles, 25 Gy to pelvis) or IMRT (76 Gy in 38 daily fractions: 50 Gy to prostate and pelvis, followed by 26 Gy prostate boost), with androgen deprivation therapy (18-24 months). The primary endpoint was acute grade ≥ 2 gastrointestinal (GI) or genitourinary (GU) toxicity occurring during radiotherapy or within 120 days after treatment completion (CTCAE v4.0). Secondary endpoints included patient-reported outcomes (Expanded Prostate Cancer Index Composite, International Prostate Symptom Score [IPSS]). RESULTS: Baseline characteristics were balanced (median age, 72 years; 49.6% prostate-specific antigen ≥ 20 ng/mL; 69% Gleason ≥ 8). Acute grade ≥ 2 GI toxicity occurred in 8.3% with SBRT versus 39.0% with IMRT (p < 0.0001); grade ≥ 2 GU toxicity in 23.3% versus 36.1%, respectively (p = 0.126). Grade 3 diarrhea occurred in one patient with IMRT; no grade ≥ 3 GU events were observed. At 1 month, bowel QoL declined more with IMRT (-10.4) than SBRT (-1.9; p = 0.0008), as did urinary domain decline (-11.3 vs -7.5). At 1 week, IPSS and QoL worsened less with SBRT than with IMRT (+4.55 vs +7.49, p = 0.062; QoL p = 0.029). CONCLUSION: Once-weekly SBRT to the prostate and pelvis significantly reduced acute GI toxicity and provided comparable GU safety relative to IMRT, with supportive early patient-reported outcomes. These findings extend SBRT evidence to the pelvis-inclusive setting in HR-PC and support phase III trials.
No takes yet. Share an insight, caveat, or question.
Poon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: